Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers

Loading...
Thumbnail Image

Date

Authors

Udugama, Maheshi
Sanij, Elaine
Voon, Hsiao P J
Son, Jinbae
Hii, Linda
Henson, Jeremy D
Chan, F Lyn
Chang, Fiona TM
Liu, Yumei
Pearson, Richard B

Journal Title

Journal ISSN

Volume Title

Publisher

National Academy of Sciences (USA)

Abstract

ATRX (alpha thalassemia/mental retardation X-linked) complexes with DAXX to deposit histone variant H3.3 into repetitive heterochromatin. Recent genome sequencing studies in cancers have revealed mutations in ATRX and their association with ALT (alternative lengthening of telomeres) activation. Here we report depletion of ATRX in mouse ES cells leads to selective loss in ribosomal RNA gene (rDNA) copy number. Supporting this, ATRX-mutated human ALT-positive tumors also show a substantially lower rDNA copy than ALT-negative tumors. Further investigation shows that the rDNA copy loss and repeat instability are caused by a disruption in H3.3 deposition and thus a failure in heterochromatin formation at rDNA repeats in the absence of ATRX. We also find that ATRX-depleted cells are reduced in ribosomal RNA transcription output and show increased sensitivity to RNA polymerase I (Pol I) transcription inhibitor CX5461. In addition, human ALT-positive cancer cell lines are also more sensitive to CX5461 treatment. Our study provides insights into the contribution of ATRX loss of function to tumorigenesis through the loss of rDNA stability and suggests the therapeutic potential of targeting Pol I transcription in ALT cancers.

Description

Keywords

Citation

Source

PNAS - Proceedings of the National Academy of Sciences of the United States of America

Book Title

Entity type

Access Statement

Open Access

License Rights

Creative Commons Attribution-NonCommercialNoDerivatives License 4.0 (CC BY-NC-ND)

Restricted until

abcd